CERO THERAPEUTICS HOLDINGS, INC. Income Tax Expense
CERO THERAPEUTICS HOLDINGS, INC. (CERO) reported Income Tax Expense of $94.82 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-04-02.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxExpenseBenefit · last filed 2024-04-02
- CERO THERAPEUTICS HOLDINGS, INC. income tax expense (benefit) for the quarter ending 2023-12-31 was $24.41K, a 95.47% decline year-over-year.
- CERO THERAPEUTICS HOLDINGS, INC. income tax expense (benefit) for the quarter ending 2023-09-30 was $25.75K, a 57.41% decline year-over-year.
- CERO THERAPEUTICS HOLDINGS, INC. income tax expense (benefit) for the quarter ending 2023-06-30 was $44.66K.
- CERO THERAPEUTICS HOLDINGS, INC. income tax expense (benefit) for the quarter ending 2023-03-31 was $0.00.
- CERO THERAPEUTICS HOLDINGS, INC. income tax expense (benefit) for fiscal 2023 was $94.82K, a 84.17% decline from fiscal 2022.
- CERO THERAPEUTICS HOLDINGS, INC. income tax expense (benefit) for fiscal 2022 was $599.16K.
| Period end | Income Tax Expense (Benefit) 3 month | Income Tax Expense (Benefit) 4 month | Income Tax Expense (Benefit) 6 month | Income Tax Expense (Benefit) 7 month | Income Tax Expense (Benefit) 9 month | Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|---|---|
| 2023-12-31 | $24.41K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-02 | $50.16K derived: sum of 2 quarters · filed 2024-04-02 | $94.82K derived: sum of 3 quarters · filed 2024-04-02 | $94.82K 10-K · filed 2024-04-02 | ||
| 2023-09-30 | $25.75K 10-Q · filed 2023-11-09 | $70.41K derived: sum of 2 quarters · filed 2023-11-09 | $70.41K 10-Q · filed 2023-11-09 | $609.11K derived: sum of 4 quarters · filed 2024-04-02 | ||
| 2023-06-30 | $44.66K 10-Q · filed 2023-08-14 | $44.66K 10-Q · filed 2023-08-14 | $583.36K derived: sum of 3 quarters · filed 2024-04-02 | $643.82K derived: sum of 4 quarters · filed 2024-04-02 | ||
| 2023-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2024-04-02 | $538.70K derived: sum of 2 quarters · filed 2024-04-02 | $599.16K derived: sum of 3 quarters · filed 2024-04-02 | |||
| 2022-12-31 | $538.70K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-02 | $599.16K derived: sum of 2 quarters · filed 2024-04-02 | $599.16K 10-K · filed 2024-04-02 | |||
| 2022-09-30 | $60.46K 10-Q · filed 2023-11-09 | $60.46K 10-Q · filed 2023-11-09 | ||||
| 2021-12-31 | -$16.87K 10-K · filed 2023-03-24 | |||||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-10 | $0.00 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |